Novartis warns MFN could reshape European drug launches

Novartis CEO Vas Narasimhan has warned that U.S. most-favored-nation (MFN) drug pricing could lead companies to delay or skip launches in European markets if government reimbursement prices are too low. His public comments describe a risk and possible future launch decisions—not a confirmed plan to stop selling to European government payers.

The concern is that U.S. prices under MFN arrangements may be benchmarked against prices in selected wealthy countries. Low government-negotiated prices in Europe could therefore put pressure on U.S. prices, giving manufacturers an incentive to change launch timing, pricing, or availability.

Narasimhan has said the impact on launches is likely to become more visible around 2027, and that Novartis is pressing European and Japanese governments to better reward pharmaceutical innovation. He has also said current direct effects on Novartis are limited, while longer-term implications could be significant.

In short:
headlines about Novartis “bypassing” government payers appear to describe a potential strategic response—delayed or selective launches, or alternative access arrangements—not a verified blanket decision to bypass European public reimbursement systems.